BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 29486179)

  • 1. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.
    Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y
    Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma.
    Isaka T; Nakayama H; Yokose T; Ito H; Miyagi Y; Matsuzaki T; Nagata M; Furumoto H; Nishii T; Katayama K; Yamada K; Masuda M
    Ann Thorac Surg; 2016 Dec; 102(6):1821-1828. PubMed ID: 27553497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer.
    Jin Y; Chen M; Yu X
    Sci Rep; 2016 Aug; 6():31636. PubMed ID: 27527915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR.
    Isaka T; Yokose T; Ito H; Nakayama H; Miyagi Y; Saito H; Masuda M
    BMC Pulm Med; 2021 Mar; 21(1):100. PubMed ID: 33757469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
    Takamochi K; Oh S; Matsunaga T; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma.
    Isaka T; Yokose T; Ito H; Nagata M; Furumoto H; Nishii T; Katayama K; Yamada K; Nakayama H; Masuda M
    Medicine (Baltimore); 2015 Oct; 94(42):e1784. PubMed ID: 26496308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
    Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-recurrence survival analysis of stage I non-small-cell lung cancer.
    Lee K; Kim HR; Kim DK; Kim YH; Park SI; Choi SH; Han J
    Asian Cardiovasc Thorac Ann; 2017 Nov; 25(9):623-629. PubMed ID: 29058973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
    BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of Spread Through Air Spaces in Resected Pathological Stage I Lung Adenocarcinoma.
    Toyokawa G; Yamada Y; Tagawa T; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Oda Y; Maehara Y
    Ann Thorac Surg; 2018 Jun; 105(6):1655-1663. PubMed ID: 29453963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
    Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
    Xu Y; Zheng M; Wang N; Wang R
    Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component.
    Kishi N; Ito M; Miyata Y; Kanai A; Handa Y; Tsutani Y; Kushitani K; Takeshima Y; Okada M
    Ann Surg Oncol; 2020 Mar; 27(3):945-955. PubMed ID: 31732945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Yoshiya T; Kai Y; Tsutani Y; Mimura T; Konishi K; Takeshima Y; Okada M
    Thorac Cancer; 2018 Dec; 9(12):1594-1602. PubMed ID: 30298562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
    Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
    Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.
    Okamoto T; Kitahara H; Shimamatsu S; Katsura M; Takada K; Fujishita T; Suzuki Y; Morodomi Y; Tagawa T; Maehara Y
    Anticancer Res; 2016 Jun; 36(6):3057-63. PubMed ID: 27272827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.